chartmojo

SRPT regression play

Corto
chartmojo Actualizado   
NASDAQ:SRPT   Sarepta Therapeutics, Inc.
3
100% pop should regress some
Comentarios:
important Duchens Muscular Dystrophy reversal/approval..small market however
Comentarios:
Frankly after researching this companies drug and Duchenne Muscular Dystrophy i find myself rooting for this company. This stock popped some 95% on an approval of their drug that delays the onset of the debilitating effects of this little known genetic disease in children. While there was and may be more regression opportunities in the price from a technical perspective, especially for a scalper like me, I'm hoping the company's stock actually ultimately goes to the moon and that those dedicated individuals involved in this company prosper because they deserve it.

Exención de responsabilidad

La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.